{"hands_on_practices": [{"introduction": "Effective clinical practice relies on translating evidence from large-scale trials into meaningful benefits for individual patients. This exercise demonstrates how to apply fundamental epidemiological concepts, such as relative and absolute risk reduction, to a common and critical scenario in stroke prevention: initiating anticoagulation for nonvalvular atrial fibrillation. By calculating the absolute risk reduction, you will develop the essential skill of quantifying the direct impact of a therapy, moving beyond percentages to understand the real-world magnitude of its effect. [@problem_id:4528539]", "problem": "A patient with Nonvalvular Atrial Fibrillation (NVAF) is being switched from antiplatelet therapy to anticoagulation for prevention of embolic ischemic stroke. Assume the following scientifically grounded quantities and conditions: the baseline annual embolic stroke risk under antiplatelet therapy is $0.06$ per patient-year, clinical trials establish a constant relative risk reduction of $0.64$ for embolic stroke when anticoagulation is used compared to antiplatelet therapy in NVAF, and anticoagulation does not alter the incidence of non-embolic stroke mechanisms. Starting from the fundamental definitions that incidence risk is the probability of event occurrence over a specified interval, that relative risk is the ratio of risks between exposed and unexposed groups, and that relative risk reduction is the complement of the relative risk, derive the absolute reduction in embolic event risk attributable to the therapy switch. Express your final numerical answer as a decimal risk per patient-year, rounded to four significant figures.", "solution": "The problem requires the derivation of the absolute risk reduction in embolic events when switching a patient with Nonvalvular Atrial Fibrillation (NVAF) from antiplatelet therapy to anticoagulation. The solution must be derived from fundamental definitions provided in the problem statement.\n\nFirst, we define the relevant quantities using symbolic notation, based on the givens:\n- Let $R_{AP}$ be the baseline annual incidence risk of embolic stroke under antiplatelet therapy. From the problem, $R_{AP} = 0.06$ per patient-year.\n- Let $R_{AC}$ be the annual incidence risk of embolic stroke under anticoagulation. This value is unknown and must be calculated.\n- Let $RRR$ be the relative risk reduction for embolic stroke with anticoagulation compared to antiplatelet therapy. From the problem, $RRR = 0.64$.\n\nThe problem asks for the absolute risk reduction, which we denote as $ARR$. The absolute risk reduction is the simple difference between the risk in the control group (antiplatelet therapy) and the risk in the treated group (anticoagulation).\n$$\nARR = R_{AP} - R_{AC}\n$$\nTo calculate $ARR$, we must first determine the value of $R_{AC}$. The problem provides definitions that link $R_{AC}$ to the known quantities.\n\nThe relative risk reduction ($RRR$) is defined as the complement of the relative risk ($RR$):\n$$\nRRR = 1 - RR\n$$\nThe relative risk ($RR$) is defined as the ratio of the risk in the exposed (treated) group to the risk in the unexposed (control) group:\n$$\nRR = \\frac{R_{AC}}{R_{AP}}\n$$\nWe can substitute the expression for $RR$ into the equation for $RRR$:\n$$\nRRR = 1 - \\frac{R_{AC}}{R_{AP}}\n$$\nNow, we can rearrange this equation to solve for the unknown risk, $R_{AC}$:\n$$\n\\frac{R_{AC}}{R_{AP}} = 1 - RRR\n$$\n$$\nR_{AC} = R_{AP} \\times (1 - RRR)\n$$\nWith this expression for $R_{AC}$, we can now substitute it back into the equation for the absolute risk reduction, $ARR$:\n$$\nARR = R_{AP} - R_{AC} = R_{AP} - \\left[ R_{AP} \\times (1 - RRR) \\right]\n$$\nDistributing the terms, we get:\n$$\nARR = R_{AP} - R_{AP} + R_{AP} \\times RRR\n$$\nThis simplifies to a direct relationship between $ARR$, $R_{AP}$, and $RRR$:\n$$\nARR = R_{AP} \\times RRR\n$$\nThis derived relationship shows that the absolute risk reduction is the baseline risk multiplied by the relative risk reduction. The provided information that anticoagulation does not alter non-embolic stroke incidence is extraneous to the calculation, as the question specifically concerns the reduction in embolic event risk.\n\nWe can now substitute the given numerical values into our derived formula:\n- $R_{AP} = 0.06$\n- $RRR = 0.64$\n$$\nARR = 0.06 \\times 0.64\n$$\nPerforming the multiplication:\n$$\nARR = 0.0384\n$$\nThe problem requires the final answer to be expressed as a decimal risk per patient-year, rounded to four significant figures. The calculated value $0.0384$ has three significant figures (the digits $3$, $8$, and $4$). To express this result with four significant figures, a trailing zero must be added.\n$$\nARR = 0.03840\n$$\nThis is the absolute reduction in embolic event risk attributable to the therapy switch, expressed per patient-year.", "answer": "$$\\boxed{0.03840}$$", "id": "4528539"}, {"introduction": "Determining the precise cause of an ischemic stroke is often complicated by the presence of multiple competing risk factors in a single patient. To address this, neurologists use standardized classification systems like TOAST and the Causative Classification System (CCS) to systematically evaluate the evidence for each potential etiology. This case-based exercise will challenge you to apply the distinct rules of these two important frameworks, honing your ability to navigate diagnostic uncertainty and understand how different classification philosophies can lead to different conclusions. [@problem_id:4528610]", "problem": "A $68$-year-old right-handed man with a $20$-year history of hypertension and a $10$-year history of type $2$ diabetes mellitus develops sudden left pure motor hemiparesis without aphasia, neglect, visual field deficit, or other cortical signs. On arrival $2$ hours after symptom onset, magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI) shows a single subcortical hyperintensity measuring $8\\ \\mathrm{mm}$ in maximal diameter in the posterior limb of the right internal capsule; there is no cortical diffusion restriction and no other acute lesions. Fluid-attenuated inversion recovery (FLAIR) shows moderate white matter hyperintensities consistent with chronic small vessel disease. Computed tomographic angiography (CTA) demonstrates approximately $55\\%$ stenosis of the right internal carotid artery by the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method; no intracranial large-vessel occlusion is present. Carotid duplex confirms right internal carotid artery peak systolic velocities consistent with approximately $55$–$60\\%$ stenosis. Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) show normal left ventricular function, no left atrial appendage thrombus, no valvular vegetations, and no patent foramen ovale. Continuous inpatient telemetry and a subsequent $72$-hour ambulatory monitor capture paroxysmal atrial fibrillation (AF) with episodes lasting $6$ to $12$ minutes, including one episode within $24$ hours preceding presentation. The patient has never been anticoagulated.\n\nUsing the core pathophysiologic definitions of ischemic stroke subtypes and the formal criteria of the Trial of Org $10172$ in Acute Stroke Treatment (TOAST) and the Causative Classification System (CCS) of Ischemic Stroke as the fundamental base, determine the most appropriate classification under each system for this event. In your reasoning, start from first principles: define the key clinicoradiographic features that separate small-artery occlusion due to lipohyalinosis from large-artery atherosclerosis and cardio-aortic embolism; explain how lesion topography and size, vascular imaging, and the presence of a high-risk cardiac source influence categorization; and apply the rules governing exclusion or downgrading of mechanisms when competing causes are present. Then select the single best combined classification.\n\nWhich option best captures the correct classification and justification?\n\nA. TOAST: Small-artery occlusion (lacunar). CCS: Small-artery occlusion — probable causative mechanism.\n\nB. TOAST: Cardioembolism. CCS: Cardio-aortic embolism — probable causative mechanism.\n\nC. TOAST: Stroke of undetermined etiology — more than one plausible cause. CCS: Small-artery occlusion — probable causative mechanism, with cardio-aortic embolism — possible.\n\nD. TOAST: Large-artery atherosclerosis. CCS: Large-artery atherosclerosis — probable causative mechanism.", "solution": "The user wants me to act as a meticulous STEM professor to solve a clinical neurology problem. This requires a formal validation of the problem statement, followed by a first-principles derivation of the solution and a critical evaluation of each option.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n-   **Patient:** A $68$-year-old right-handed man.\n-   **History:** $20$-year history of hypertension; $10$-year history of type $2$ diabetes mellitus.\n-   **Clinical Presentation:** Sudden-onset left pure motor hemiparesis.\n-   **Negative Clinical Signs:** No aphasia, neglect, visual field deficit, or other cortical signs.\n-   **Timeline:** Arrival at $2$ hours after symptom onset.\n-   **MRI Findings:**\n    -   Diffusion-weighted imaging (DWI): A single subcortical hyperintensity measuring $8\\ \\mathrm{mm}$ in maximal diameter in the posterior limb of the right internal capsule.\n    -   No cortical diffusion restriction or other acute lesions.\n    -   Fluid-attenuated inversion recovery (FLAIR): Moderate white matter hyperintensities consistent with chronic small vessel disease.\n-   **Vascular Imaging Findings:**\n    -   Computed tomographic angiography (CTA): Approximately $55\\%$ stenosis of the right internal carotid artery by the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method. No intracranial large-vessel occlusion.\n    -   Carotid duplex: Confirms right internal carotid artery peak systolic velocities consistent with approximately $55$–$60\\%$ stenosis.\n-   **Cardiac Evaluation:**\n    -   Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE): Normal left ventricular function, no left atrial appendage thrombus, no valvular vegetations, and no patent foramen ovale.\n    -   Cardiac Monitoring (inpatient telemetry and $72$-hour ambulatory): Paroxysmal atrial fibrillation (AF) with episodes lasting $6$ to $12$ minutes; one episode occurred within $24$ hours preceding presentation.\n-   **Medication History:** Never been anticoagulated.\n-   **Required Framework:** Analysis must use the core pathophysiologic definitions of stroke subtypes and the formal criteria of the Trial of Org $10172$ in Acute Stroke Treatment (TOAST) and the Causative Classification System (CCS) of Ischemic Stroke.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem statement is a clinical vignette that is consistent and scientifically grounded.\n-   **Scientifically Grounded (Critical):** The presentation, risk factors, and diagnostic findings are medically and scientifically accurate. The scenario describes a common clinical puzzle in stroke neurology. The referenced classification systems (TOAST, CCS) are established and widely used in clinical practice and research. The problem does not violate any fundamental principles of neurology or pathophysiology.\n-   **Well-Posed:** The problem is well-posed. It provides sufficient data to apply the specified classification systems. The core challenge arises from the presence of multiple potential etiologies, which is a recognized category within these systems and not an indication of a flawed problem setup. The question asks for a specific classification based on these data and systems, which allows for a unique, derivable answer.\n-   **Objective (Critical):** The language is objective and devoid of subjective claims. It presents clinical and radiological facts.\n\nThe problem does not exhibit any of the listed flaws (e.g., scientific unsoundness, incompleteness, contradiction, or ambiguity). It is a complex but valid problem requiring detailed application of established clinical classification rules.\n\n**Step 3: Verdict and Action**\nThe problem is **valid**. The solution process will now proceed.\n\n### Solution Derivation\n\nThe task is to classify an ischemic stroke event using two different formal systems, TOAST and CCS, based on the provided clinical and diagnostic data. The core challenge is the presence of evidence supporting three distinct potential mechanisms: small-artery occlusion, cardioembolism, and large-artery atherosclerosis.\n\n**1. Foundational Principles of Stroke Etiology**\n\n-   **Small-Artery Occlusion (SVO) / Lacunar Stroke:** This mechanism involves the occlusion of a single, small-caliber perforating artery supplying deep brain structures. The underlying pathology is typically lipohyalinosis or microatheroma, secondary to chronic hypertension and diabetes. The resulting infarct is small (classically less than $15\\ \\mathrm{mm}$ in diameter) and subcortical, leading to a \"lacunar syndrome\" (e.g., pure motor hemiparesis, pure sensory stroke) without cortical signs like aphasia or neglect. The patient's presentation—pure motor hemiparesis, an $8\\ \\mathrm{mm}$ infarct in the internal capsule, a history of hypertension and diabetes, and background small vessel disease on FLAIR—is the archetypal phenotype for SVO.\n\n-   **Cardioembolism (CE):** This mechanism involves the formation of a thrombus within the heart, which then embolizes to a cerebral artery. Atrial fibrillation (AF) is a major, high-risk source for CE. Emboli from the heart are often of variable size and can occlude large or small vessels. While they classically cause larger, wedge-shaped cortical infarcts, it is possible for a small embolus to occlude a single deep perforator, mimicking a lacunar stroke. The patient has newly detected paroxysmal AF, which constitutes a high-risk cardioembolic source.\n\n-   **Large-Artery Atherosclerosis (LAA):** This mechanism is caused by atherosclerosis in a large extracranial (e.g., carotid) or intracranial artery. The stroke can result from artery-to-artery embolism from a plaque, or from hemodynamic insufficiency due to severe stenosis or occlusion. For a stroke to be attributed to LAA, there must be evidence of significant (typically defined as $\\geq50\\%$) stenosis or occlusion in the artery supplying the territory of the infarct. The patient has a $55$-$60\\%$ stenosis in the ipsilateral internal carotid artery, meeting this minimum criterion.\n\n**2. Application of the TOAST Classification System**\n\nThe TOAST system is a hierarchical and largely exclusionary classification scheme.\n\n-   **Category 1: Large-Artery Atherosclerosis:** The patient has a $\\ge50\\%$ stenosis ($55$-$60\\%$) in the ipsilateral internal carotid artery. Thus, the patient meets the criteria for this category.\n-   **Category 2: Cardioembolism:** The patient has a high-risk cardiac source (paroxysmal AF). Thus, the patient also meets the criteria for this category.\n-   **Category 3: Small-Artery Occlusion (Lacunar):** This category requires a classic lacunar clinical syndrome and a corresponding subcortical infarct of less than $1.5\\ \\mathrm{cm}$ ($15\\ \\mathrm{mm}$) diameter. The patient's presentation fits this perfectly. However, a crucial exclusionary rule in the TOAST definition states that this category applies only if there is **no** evidence of a potential cardioembolic source and **no** ipsilateral arterial stenosis of $\\ge50\\%$. Since this patient has both, the diagnosis of SVO under TOAST is formally excluded.\n-   **Category 5: Stroke of Undetermined Etiology:** This category is used when the cause cannot be definitively assigned. It has a specific subcategory: **\"Two or more causes identified\"**. This subcategory is explicitly for cases where the patient meets the criteria for more than one potential etiology. In this case, the patient meets the criteria for both LAA and CE.\n\nTherefore, according to the strict rules of the TOAST classification, the correct category is **\"Stroke of undetermined etiology due to more than one cause identified\"**.\n\n**3. Application of the Causative Classification System (CCS)**\n\nThe CCS is a more modern, evidence-based system that allows for a more nuanced assessment, including assigning probabilities to different causes. It places significant weight on the stroke \"phenotype\" (i.e., the combination of clinical syndrome and infarct pattern/location).\n\n-   The system assesses the strength of evidence for each potential cause.\n-   **Evidence for SVO:** The evidence is very strong. The clinical syndrome (pure motor), infarct location (posterior limb of internal capsule), infarct size ($8\\ \\mathrm{mm}$), and background risk factors/imaging (hypertension, diabetes, chronic white matter changes) create a classic lacunar phenotype.\n-   **Evidence for CE:** The evidence consists of paroxysmal AF. However, the lacunar phenotype is atypical for cardioembolism. CCS considers the infarct pattern as a key piece of evidence for discerning the *causative* mechanism for the specific event versus merely identifying a *risk factor*.\n-   **Evidence for LAA:** The evidence is a moderate, non-hemodynamically significant ($55$-$60\\%$) carotid stenosis. This is a relatively weak link for causing a single, deep perforator infarct compared to the strong evidence for intrinsic small-vessel pathology.\n\nThe CCS algorithm is designed to handle such cases of competing causes. For a single perforator-territory infarct of $20\\,\\mathrm{mm}$ diameter, the classification is **\"Small-artery occlusion\"** unless there is high-grade ($\\ge70\\%$) stenosis or occlusion of the parent large artery, or a very high-risk embolic source with no other good explanation. Given the classic lacunar infarct Ccs prioritizes the phenotype. The system would classify this event as **\"Small-artery occlusion — probable causative mechanism\"**. The other potential causes (CE from AF, LAA from moderate stenosis) would be listed as **\"possible\"** but are not considered the primary cause of this specific event.\n\n**4. Evaluation of Options**\n\n-   **A. TOAST: Small-artery occlusion (lacunar). CCS: Small-artery occlusion — probable causative mechanism.**\n    -   The TOAST classification is **Incorrect**. The presence of AF and $\\ge50\\%$ stenosis are explicit exclusion criteria for the SVO category in TOAST.\n    -   The CCS classification is plausible, but the entire option is invalidated by the incorrect TOAST classification.\n\n-   **B. TOAST: Cardioembolism. CCS: Cardio-aortic embolism — probable causative mechanism.**\n    -   The TOAST classification is **Incorrect**. It should be \"undetermined etiology\" because criteria for both CE and LAA are met. One cannot be chosen over the other.\n    -   The CCS classification is **Incorrect**. The classic lacunar phenotype makes SVO a far more probable cause than CE for this specific event.\n\n-   **C. TOAST: Stroke of undetermined etiology — more than one plausible cause. CCS: Small-artery occlusion — probable causative mechanism, with cardio-aortic embolism — possible.**\n    -   The TOAST classification is **Correct**. As derived above, the patient meets criteria for both LAA and CE, mandating the classification \"Stroke of undetermined etiology — more than one plausible cause\".\n    -   The CCS classification is **Correct**. As derived above, CCS prioritizes the classic lacunar phenotype, assigning \"Small-artery occlusion — probable causative mechanism\" as the primary diagnosis, while appropriately acknowledging the AF as a \"possible\" co-existing factor. This option accurately reflects the outputs of both systems.\n\n-   **D. TOAST: Large-artery atherosclerosis. CCS: Large-artery atherosclerosis — probable causative mechanism.**\n    -   The TOAST classification is **Incorrect**. As with option B, it should be \"undetermined etiology\" because criteria for both LAA and CE are met.\n    -   The CCS classification is **Incorrect**. The moderate stenosis is a weaker explanation for this specific lacunar infarct than intrinsic small-vessel disease.\n\n### Conclusion\nOption C provides the only classification that is consistent with the formal rules of both the TOAST and CCS systems when applied to the given clinical data. The discrepancy between the two systems highlights their different methodologies: TOAST's rigid, exclusionary hierarchy versus CCS's phenotype-driven, probabilistic approach.", "answer": "$$\\boxed{C}$$", "id": "4528610"}, {"introduction": "The pinnacle of clinical decision-making in stroke prevention involves balancing the benefit of reducing ischemic events against the harm of potential treatment complications, such as major bleeding. This advanced problem simulates this complex judgment by integrating multiple quantitative tools: a clinical risk score (HAS-BLED), disease-specific risk data, and patient-centered outcomes (Quality-Adjusted Life-Years, or QALYs). By synthesizing these elements, you will practice a comprehensive, data-driven approach to justify a therapeutic choice for a high-risk patient, mirroring the sophisticated analysis required in modern neurology. [@problem_id:4528567]", "problem": "A $78$-year-old man with paroxysmal atrial fibrillation presents after a lacunar infarct consistent with small-vessel disease. He has long-standing hypertension with systolic blood pressure $168$ mm Hg, Type $2$ diabetes mellitus, chronic kidney disease stage $3b$ with estimated glomerular filtration rate (eGFR) $42$ mL/min, and stable coronary artery disease. He denies prior major bleeding. He is not on warfarin and has no International Normalized Ratio (INR) data. He currently takes an oral nonsteroidal anti-inflammatory drug (NSAID) for osteoarthritis and low-dose aspirin, which his neurologist will discontinue if anticoagulation is initiated. He does not consume alcohol.\n\nYou are asked to apply the Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol (HAS-BLED) score to estimate his bleeding risk and to balance this against his stroke risk by etiologic category to justify anticoagulation. Use the following assumptions derived from a validated institutional cohort:\n\n1. HAS-BLED scoring follows standard definitions: Hypertension (systolic blood pressure greater than $160$ mm Hg) $=1$ point; Abnormal renal or liver function $=1$ point each (maximum $2$); prior Stroke $=1$; Bleeding history or predisposition $=1$; Labile INR $=1$; Elderly (age greater than $65$ years) $=1$; Drugs predisposing to bleeding (antiplatelets or NSAIDs) or alcohol use $=1$ point each (maximum $2$). Compute the patient’s HAS-BLED score $h$.\n\n2. The annual major bleeding risk without anticoagulation predicted by HAS-BLED is given by\n$$\nr_{\\text{bleed}}(h) \\;=\\; 0.005 \\;+\\; 0.005\\,h \\;+\\; 0.002\\,h^{2},\n$$\nexpressed as events per patient-year.\n\n3. The patient’s total annual ischemic stroke risk without anticoagulation is $r_{\\text{stroke,tot}}=0.096$ events per patient-year. Of this risk, $65\\%$ is cardioembolic (embolus from atrial fibrillation), $25\\%$ is small-vessel disease, and $10\\%$ is large-artery thrombotic disease.\n\n4. A Direct Oral Anticoagulant (DOAC) reduces the cardioembolic stroke component by $66\\%$ and leaves small-vessel and large-artery thrombotic stroke risks unchanged.\n\n5. Initiation of a DOAC multiplies the patient’s major bleeding risk (relative to no anticoagulation) by $1.30$.\n\n6. For decision-analytic balancing, use quality-adjusted life-year (QALY) loss weights: each cardioembolic ischemic stroke incurs an average QALY loss of $w_{\\text{emb}}=3.2$, and each major bleed incurs an average QALY loss of $w_{\\text{bleed}}=0.9$.\n\nUsing first principles of expected value, compute the net change in expected QALYs per year with DOAC therapy relative to no anticoagulation, defined as the expected QALYs gained from prevented cardioembolic strokes minus the expected QALYs lost from additional major bleeds attributable to the DOAC. Express the final net change in QALYs per year as a single real number and round your answer to four significant figures. Do not include any unit symbols in your final boxed answer.", "solution": "The problem statement is assessed to be valid. It is self-contained, scientifically grounded in medical decision analysis principles, and provides a well-posed quantitative task with all necessary data and unambiguous definitions.\n\nThe objective is to compute the net change in expected quality-adjusted life-years (QALYs) per year when initiating Direct Oral Anticoagulant (DOAC) therapy. This is calculated as the expected QALYs gained from preventing ischemic strokes minus the expected QALYs lost from causing additional major bleeds.\n\nFirst, we must calculate the patient's HAS-BLED score, denoted as $h$. According to the provided scoring rules:\n- **H**ypertension (systolic blood pressure $ 160$ mm Hg): The patient's SBP is $168$ mm Hg, which is greater than $160$ mm Hg. This contributes $1$ point.\n- **A**bnormal renal or liver function: The patient has chronic kidney disease stage $3b$ with an eGFR of $42$ mL/min, which constitutes abnormal renal function. This contributes $1$ point. There is no information on liver function.\n- **S**troke: The patient has a history of a lacunar infarct. This contributes $1$ point.\n- **B**leeding history or predisposition: The patient denies prior major bleeding, and no other inherent predisposition is mentioned. This contributes $0$ points.\n- **L**abile INR: The patient is not on warfarin and has no INR data. This contributes $0$ points.\n- **E**lderly (age $ 65$ years): The patient's age is $78$ years, which is greater than $65$ years. This contributes $1$ point.\n- **D**rugs or alcohol: The patient takes an oral NSAID and aspirin. The rule states \"$1$ point each (maximum $2$)\" for \"Drugs predisposing to bleeding (antiplatelets or NSAIDs) or alcohol use\". The use of an antiplatelet (aspirin) and an NSAID falls into the drug category, contributing $1$ point. The patient does not consume alcohol, contributing $0$ points. Thus, this criterion adds a total of $1$ point.\n\nSumming these points gives the total HAS-BLED score:\n$$\nh = 1 (\\text{H}) + 1 (\\text{A}) + 1 (\\text{S}) + 0 (\\text{B}) + 0 (\\text{L}) + 1 (\\text{E}) + 1 (\\text{D}) = 5\n$$\n\nNext, we calculate the patient's annual major bleeding risk without anticoagulation, $r_{\\text{bleed}}(h)$, using the provided formula and $h=5$:\n$$\nr_{\\text{bleed}}(h) = 0.005 + 0.005h + 0.002h^{2}\n$$\n$$\nr_{\\text{bleed}}(5) = 0.005 + 0.005(5) + 0.002(5)^{2} = 0.005 + 0.025 + 0.002(25) = 0.030 + 0.050 = 0.080 \\text{ events/year}\n$$\nInitiating a DOAC multiplies this risk by a factor of $1.30$. The new bleeding risk is:\n$$\nr_{\\text{bleed, DOAC}} = 1.30 \\times r_{\\text{bleed}}(5) = 1.30 \\times 0.080 = 0.104 \\text{ events/year}\n$$\nThe increase in the annual rate of major bleeding attributable to the DOAC, $\\Delta r_{\\text{bleed}}$, is:\n$$\n\\Delta r_{\\text{bleed}} = r_{\\text{bleed, DOAC}} - r_{\\text{bleed}}(5) = 0.104 - 0.080 = 0.024 \\text{ events/year}\n$$\n\nNow, we calculate the reduction in ischemic stroke risk. The total annual risk without anticoagulation is $r_{\\text{stroke,tot}} = 0.096$. Of this, $65\\%$ is cardioembolic. The baseline annual rate of cardioembolic stroke is:\n$$\nr_{\\text{emb, noAC}} = 0.65 \\times r_{\\text{stroke,tot}} = 0.65 \\times 0.096 = 0.0624 \\text{ events/year}\n$$\nDOAC therapy reduces this cardioembolic component by $66\\%$. The reduction in the annual rate of cardioembolic strokes, $\\Delta r_{\\text{emb}}$, is:\n$$\n\\Delta r_{\\text{emb}} = 0.66 \\times r_{\\text{emb, noAC}} = 0.66 \\times 0.0624 = 0.041184 \\text{ events/year}\n$$\nThe risks of small-vessel and large-artery stroke are unchanged.\n\nFinally, we compute the net change in expected QALYs per year. The QALY loss for a cardioembolic stroke is $w_{\\text{emb}} = 3.2$, and for a major bleed is $w_{\\text{bleed}} = 0.9$.\n\nThe expected QALYs gained per year is the product of the reduction in cardioembolic stroke rate and the QALY loss per stroke:\n$$\n\\Delta Q_{\\text{gain}} = \\Delta r_{\\text{emb}} \\times w_{\\text{emb}} = 0.041184 \\times 3.2 = 0.1317888 \\text{ QALYs/year}\n$$\nThe expected QALYs lost per year is the product of the increase in major bleeding rate and the QALY loss per bleed:\n$$\n\\Delta Q_{\\text{loss}} = \\Delta r_{\\text{bleed}} \\times w_{\\text{bleed}} = 0.024 \\times 0.9 = 0.0216 \\text{ QALYs/year}\n$$\nThe net change in expected QALYs per year, $\\Delta Q_{\\text{net}}$, is the difference between the QALYs gained and the QALYs lost:\n$$\n\\Delta Q_{\\text{net}} = \\Delta Q_{\\text{gain}} - \\Delta Q_{\\text{loss}} = 0.1317888 - 0.0216 = 0.1101888 \\text{ QALYs/year}\n$$\nThe problem requires the answer to be rounded to four significant figures.\n$$\n\\Delta Q_{\\text{net}} \\approx 0.1102\n$$\nThis positive value indicates a net benefit from DOAC therapy in terms of quality-adjusted life expectancy for this patient.", "answer": "$$\\boxed{0.1102}$$", "id": "4528567"}]}